

the cells of the invention possessed *in vivo* the hexagonal phenotypic characteristics of the primary retinal pigment epithelial cells, even though these characteristics were lost *in vitro* (FIG. 11). This result was clear when the transplant has more than one layer of cells.

*In the Claims:*

Cancel Claims 2-9, 11-23, and 25-36.

Please replace pending claim 1 with the following amended claim:

1. An injectable, non-tumorigenic, human retinal pigment epithelial cell line, wherein the cell line is selected from the group comprising hRPE-7, hRPE-116 and ARPE-19 wherein the cells of the cell line:
- (a) comprise an expression vector comprising a polynucleotide coding for a polypeptide selected from the group comprising BDNF, NT-4, CNTF, Axokine, FGF-2 (bFGF), IGF I, IGF II, TGF $\beta$ -II, Midkine, IL-1 $\beta$ , TNF, NGF, IL-2/3, ILF, IL-6, NTN, Neublastin, VEGF, GDNF, PDGF, LEDGF and PEDF.
  - (b) can non-tumorigenically interact with retinal cells of a mammalian host.

Please replace pending claim 10 with the following amended claim:

10. The cell line, human retinal pigment epithelial-7 (hRPE-7) and human retinal pigment epithelial-116 (hRPE-116)

Please replace pending claim 24 with the following amended claim:

24. A method of producing a therapeutic polypeptide to treat primary or secondary ophthalmologic or neurological disorders, comprising incubating cells of a mammalian retinal pigment epithelial cell line wherein the cell line is selected from the group comprising hRPE-7, hRPE-116 and ARPE-19 in a biological compatible medium such that the cell line produce the polypeptide and wherein the cells of the cell line comprise an expression vector comprising a polynucleotide coding for a polypeptide selected from the group comprising BDNF, NT-4, CNTF, Axokine, FGF-2 (bFGF), IGF I, IGF II,

SUB  
B3  
C5N4 as cont

~~TGFβ-II, Midkine, IL-1β, TNF, NCF, IL-2/3, ILF, IL-6, NTN, Neublastin, VEGF,  
GDNF, PDGF, LEDGF and PEDF.~~

---

Please add the following new claim:

---

SUB  
B4 as

37. The cell line IO/JG2/1, deposited under I-1695 on April 18, 1996 in the Collection Nationale de Cultures de Micro-organismes held by the Insitute Pasteur, Paris France.

---